title: [New pharmacological treatment methods of type 2 diabetes].
abstract: The variable pathogenesis and progressive nature of type 2 diabetes emphasise the need for new antidiabetic treatments. The long acting glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors have improved the treatment. Novel approaches include inhibitors of sodium glucose co-transporter 2, which increase renal glucose elimination, G-protein-coupled receptor agonists, which potentiate insulin and incretin hormone secretion. Proof of principle has been shown for glucagon receptor agonists, glucokinase activators and treatment with dual intestinal peptides, which all induce weight loss and improve glucose tolerance.
authors.affiliation: Endokrinologisk Afdeling, Hvidovre Hospital, Kettegård Alle 30, 2650 Hvidovre, Denmark. sten.madsbad@hvh.regionh.dk
authors.forename: Sten
authors.initials: S
authors.lastname: Madsbad
authors.forename: Kjeld
authors.initials: K
authors.lastname: Hermansen
mesh_terms: D001572:Benzofurans / Q000008:administration & dosage / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000494:pharmacology; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000819:agonists / Q000031:analogs & derivatives / Q000494:pharmacology; D000067757:Glucagon-Like Peptide-1 Receptor; D005941:Glucokinase / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000494:pharmacology; D043562:Receptors, G-Protein-Coupled / Q000819:agonists; D018027:Receptors, Glucagon / Q000819:agonists; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013450:Sulfones / Q000008:administration & dosage / Q000494:pharmacology; D015431:Weight Loss / Q000187:drug effects
chemical_list: D001572:Benzofurans; D054873:Dipeptidyl-Peptidase IV Inhibitors; D018491:Dopamine Agonists; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D010456:Peptides, Cyclic; D043562:Receptors, G-Protein-Coupled; D018027:Receptors, Glucagon; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013450:Sulfones; C557331:TAK-875; C571886:insulin degludec; D052216:Glucagon-Like Peptide 1; D005941:Glucokinase